Please login to the form below
Florence 2.0
This page shows the latest Florence 2.0 news and features for those working in and with pharma, biotech and healthcare.
WHO unveils AI-powered digital health worker, Florence 2.0
The beta version of Florence 2.0 was released by WHO at the WISH conference to interact with scientists, public health organisations, entrepreneurs, and policymakers. ... Commenting on the unveiling, Nick Bradshaw, director of partnerships and outreach
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Digital technology: a significant change in healthcare innovation
One example, Florence 2.0, is an AI-powered digital health worker that helps users plan and implement a healthier lifestyle through customised advice and encouragement.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Kite and Arcellx close multiple myeloma collaboration agreement
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EU outlines measures to mitigate antibiotic shortage across Europe
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EC launches cancer imaging initiative to accelerate innovation and early diagnosis
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
